Abstract-Despite the vast improvements of cell therapy in spinal cord injury treatment, no optimum protocol has been developed for application of neural stem/progenitor cells. In this regard, the present meta-analysis showed that the efficacy of the neural stem/progenitor cell (NSPC) transplantation depends mainly on injury model, intervention phase, transplanted cell count, immunosuppressive use, and probably stem cell source. Improved functional recovery post NSPC transplantation was found to be higher in transection and contusion models. Moreover, NSPC transplantation in acute phase of spinal injury was found to have better functional recovery. Higher doses (>3 Â 10 6 cell/kg) were also shown to be optimum for transplantation, but immunosuppressive agent administration negatively affected the motor function recovery. Scaffold use in NSPC transplantation could also effectively raise functional recovery. Ó 2016 Published by Elsevier Ltd. on behalf of IBRO. 
INTRODUCTION
Spinal cord injury (SCI) which is one of the most dangerous nervous system disorders, commonly affects younger population, and causes persistent and longterm disabilities. Unfortunately, about 90% of the patients suffer from long-term motor dysfunctions and approximately 78% experience moderate to severe pain. SCI and its complications impose great direct and indirect financial burdens; the annual treatment cost for each patient is estimated to be 26,270 dollars (Mann et al., 2013) .
SCI is regarded as one of the main causes of motor dysfunction and neuropathic pain. There is no cure for it and most of the therapeutic modalities are only symptomatic (Finnerup, 2013; Sharp et al., 2012; Kumru et al., 2013; Nasirinezhad et al., 2015b) . Pharmacotherapy holds the base of current treatment with little influence on functional recovery with only 30-40% decrease in neuropathic pain symptoms (Finnerup et al., 2005; Backonja et al., 2006) . Besides, numerous medication adverse side effects are the major obstacles for the long-term use (Marineo et al., 2012; Hosseini et al., 2014; Nasirinezhad et al., 2015a) . Motor dysfunction and neuropathic pain will persist unless the injured region recovers or pain control pathways reinforce. However, neurogenesis rarely occurs in central nervous system and self-healing in injured cells is rather limited. Accordingly, researchers are investigating to find methods to improve cell restoration. Currently, cell transplantation is considered as an appropriate choice for treating SCIs. According to the recent studies, cell therapy can create new neural connections which would then lead to neuropathic pain alleviation and improved functional recovery (Guenot et al., 2007; Hama and Sagen, 2007) .
Various cell populations can be used for SCI treatment.
Survival and differentiation of the transplanted cells are mainly influenced by host-related factors as well as innate properties. For instance, having been injected in brain neurogenic regions, such as the hippocampus or sub-ventricular zones, neural stem/progenitor cells (NSPCs) exhibit acceptable differentiation (Sun et al., 2011) ; but when transplanted in other parts of the nervous system, low survival and differentiation are observed (Mark Richardson et al., 2005) .
Neuroscience 322 (2016) Based on these findings, one may conclude that in vivo transplanted cell outcome is determined by innate characteristics and transplantation location.
Studies have shown that NSPCs are subject to renewal and can produce main neural cell phenotypes (neurons, oligodendrocytes and astrocytes) after transplantation in injured spinal cord (Tarasenko et al., 2007) . These cells can also modulate immune and inflammatory responses (Lee et al., 2008a; Bacigaluppi et al., 2009; Ottoboni et al., 2015) . Hence, as proposed by many studies, NSPCs may be the best choice in transplantation treatment for physiologic repair of the lesion, functional recovery and neuropathic pain relief in patients with SCIs (Bottai et al., 2008; Abematsu et al., 2010; Amemori et al., 2013) . On the other hand, some researchers believe that these cells are not significantly effective in spinal lesion treatment (Macias et al., 2006; Nutt et al., 2013) . These discrepancies might be due to the differences in treatment protocols, number of transplanted cells, application of co-treatments, source of extracted cells, and etc. In this regard, a systematic review showed that no consensus has been reached on the optimal source of NSPCs and their application in various models of spinal cord injuries, severity of injuries, and treatment protocol (Tetzlaff et al., 2011) .
So, there is no reliable and comprehensive review to judge whether NSPC transplantation is really a suitable therapeutic protocol for SCIs. Conceivably, a metaanalysis seems to be an appropriate alternative solution for this problem. Recently, few meta-analyses were performed on the subject but none evaluated neural stem cells. In the previous meta-analysis we showed that bone marrow-derived mesenchymal stem cell application improved mechanical allodynia but had no significant effects on hyperalgesia (Hosseini et al., 2015) . Accordingly, this study aimed to conduct a systematic review and meta-analysis to assess the efficacy of NSPCs on functional recovery and neuropathic pain relief in animal models of SCI.
METHODS

Search strategy
Two independent reviewers carried out an extended search in electronic databases of Medline (via PubMed), EMBASE (via OvidSP), CENTRAL, SCOPUS, Web of Science (BIOSIS), and ProQuest finding papers published until the end of December, 2015. Search strategy was based on keywords related to ''neural stem cells", ''neural progenitor stem cell" and ''neural precursor cell" in combination with terms related to ''spinal cord injuries". The combined terms in two databases of Medline and EMBASE are presented in Panel 1. In order to prevent omission of related studies, keywords were chosen as extensive as possible. Keywords were extracted from Mesh, EMTREE, and via manual search in titles and abstracts of the articles.
Additionally, PubMed search was not limited to Medline. Archived articles in PubMed Central were also screened. In order to further include non-indexed reports, search was also conducted in Google search engine and Google Scholar. Two strategies were pursued to gather gray literature: (a) authors of related articles were contacted via email to ask for unpublished data or dissertations and unrecorded data, (b) ProQuest database was meticulously searched for related dissertations. In cases where the article was not available online, the author was contacted. If there were no answers, a reminder was sent to the author, one week later. In case of no reply, other authors of the article were contacted through social networks including ResearchGate and LinkedIn, asking for the data. Two studies were obtained using this method.
To find additional articles, hand-search was performed in the bibliographies of relevant studies which yielded inclusion of two more articles. Moreover, journal hand-searching was also carried out. To do so, gathered studies were entered the EndNote X7 software and a list of highly focused journals with the highest number of articles on the subjects of stem cell therapy, neuroscience and spine was provided. All issues of the selected journals were manually screened and three more articles added to this strategy.
Inclusion criteria
In the present survey, all controlled studies evaluating neural stem cell effects on functional recovery and sensory improvement after SCIs were included. No temporal or linguistic restrictions were considered. Included studies were in vivo animal models (nonhuman), in which SCI was induced through compression, contusion, hemisection or transection models with no age, gender or phylum restrictions. A four-week gap during the follow up period was considered as exclusion criterion, since the minimum amount of time needed for the cell therapy effects on functional recovery and sensory improvement is three to four weeks. Surveys lacking control groups (sham, saline-treated or vehicle treated groups) were also excluded.
Quality assessment and data extraction
Duplicate articles were removed using EndNote software (version X7, Thomson Reuters, 2011) . Two of the authors (M.Y and S.S) independently examined the titles and abstracts of the articles and screened potentially eligible studies. Then, study full-texts were investigated and surveys met with the inclusion criteria were selected. Data extraction performed by researchers blinded to the author, journal and organization of the studies. Data recorded in a checklist designed based on PRISMA statement guidelines (Moher et al., 2009) . The data included: (i) animal characteristics (number, recipient species, gender, weight), (ii) SCI model details including injury model, severity and location, (iii) cell therapy protocol as time interval between injury and treatment, delivery route, antibiotics application and immunosuppressive agents use, transplanted cell count, (iv) graft type (allogeneic or xenogeneic), (v) extracted neural stem cells characteristics including donor species, embryonic or adult source, (vi) follow-up duration (vii) outcome (motor function and neuropathic pain symptoms), and (viii) probable biases. Reviewers' disagreements were discussed with a third reviewer and settled through mutual cooperation (93% agreement). For quality assessment, each study was assigned a score of good, fair or poor, based on a 19-item checklist recommendation of Antonic et al. (Antonic et al., 2013) and Hassannejad et al. (Hassannejad et al., 2015) studies.
Data synthesis
Outcomes assessed included functional recovery and neuropathic pain symptoms (allodynia and hyperalgesia). Data were recorded as mean and standard error. In case data were presented as charts, the data extraction method proposed by Sistrom and Mergo was utilized (Sistrom and Mergo, 2000) . When outcomes were reported in multiple stages of the survey, only the last reported figures were included. If multiple reports were given for the same population, the study with the largest sample size and the longest follow-up period would be included. In non-extracted data studies, the author was contacted and asked for the required information.
Statistical analysis
Data were summarized and entered in the STATA 11.0 statistical software in mean and standard deviation formats. In case standard errors were presented, standard deviations were calculated according to the study sample size. For each individual comparison, based on Hedges' g, a standardized mean difference (SMD) was calculated with a confidence interval of 95% (95% CI) and then a pooled effect size was presented. Publication bias was examined through Egger's and Begg's tests and funnel plots drawing (Egger et al., 1997) . Heterogeneity was assessed using Chi-squared and I 2 tests. A p value of 0.1 or less and an I 2 greater than 50% were considered as existence of heterogeneity. Fixed effect model was used for homogenous studies, and if the positive heterogeneity held, subgroup analysis was performed to determine its source. Random effects model was fitted for cases of unidentified heterogeneity source. Subgroup analysis was carried out based on animal gender, recipient species (mice, rat, and so), injury model (contusion, compression, hemisection, transection), location (cervical, thoracic, lumbar), and severity (moderate, severe), stem cell origin (brain, spine, other), intervention phase (acute, sub-acute, chronic), delivery route (intra spinal and so), graft type (allogeneic, xenogeneic), stem cell type (wild type NSPC; induced pluripotent stem cell-derived NSPC), number of transplanted cells, donor species (mice, rat, human, other), and age range (fetal, newborn, adult), co-treatment use, antibiotic, or immunosuppressive agents, observer neutrality, and follow-up period (less than 8 weeks, equal to, or more than 8 weeks). Eight weeks follow up was set based on the functional recovery duration in which plateau is being reached. It is worth mentioning that meta-analyses were carried out only if the data were reported by at least three studies.
RESULTS
Characteristics of the included studies
Search in electronic sources yielded 10,153 nonduplicated studies. Screening through titles and abstracts found 298 articles, 81 of which met the inclusion criteria. A total of 74 studies were included in the meta-analysis at last (Teng et al., 2002; Cummings et al., 2005; Hofstetter et al., 2005; Iwanami et al., 2005; Okada et al., 2005; Pallini et al., 2005; KarimiSharp et al., 2014; Yuan et al., 2014; Iwai et al., 2015; Liu et al., 2015; Pomeshchik et al., 2015; Romanyuk et al., 2015; Salewski et al., 2015a,b; Yao et al., 2015; Yokota et al., 2015) . Search flowchart and selection methods are presented in Fig. 1 . These studies comprised 125 separate experiments whose data were included in the final analysis. In 60 studies, subject motor function was only evaluated (Cummings et al., 2005; Iwanami et al., 2005; Okada et al., 2005; Pallini et al., 2005; Ziv et al., 2006; Guo et al., 2007 Guo et al., , 2012 Parr et al., 2007 Parr et al., , 2008a Tarasenko et al., 2007; Zhang et al., 2007; Bottai et al., 2008; Lowry et al., 2008; Pan et al., 2008; Hooshmand et al., 2009; Kumagai et al., 2009; Lee et al., 2009; Abematsu et al., 2010; Chen et al., 2010; Johnson et al., 2010; Tsuji et al., 2010; Yamane et al., 2010; Du et al., 2011; Kim et al., 2011 Kim et al., , 2012 Nori et al., 2011; Wang et al., 2011 Wang et al., , 2014 Xu et al., 2011; Yasuda et al., 2011; Cheng et al., 2012; Cusimano et al., 2012; Fujimoto et al., 2012; Gu et al., 2012; Kobayashi et al., 2012; Lu et al., 2012 Lu et al., , 2014 Amemori et al., 2013 Amemori et al., , 2015 He et al., 2013; Kumamaru et al., 2013; Nishimura et al., 2013; Nutt et al., 2013; Park et al., 2013; Xia et al., 2013; Yang et al., 2013; Hong et al., 2014; Hwang et al., 2014; Iwasaki et al., 2014; Nemati et al., 2014; Ormond et al., 2014; Sharp et al., 2014; Yuan et al., 2014; Iwai et al., 2015; Liu et al., 2015; Pomeshchik et al., 2015; Romanyuk et al., 2015; Yokota et al., 2015; Salewski et al., 2015a) and in five just sensory status was assessed Luo et al., 2013; Piltti et al., 2013a,b; Yao et al., 2015) . These elements were both simultaneously assessed in 10 surveys (Teng et al., 2002; Hofstetter et al., 2005; KarimiAbdolrezaee et al., 2006 KarimiAbdolrezaee et al., , 2010 Macias et al., 2006; Salazar et al., 2010; Sontag et al., 2013; van Gorp et al., 2013; Amemori et al., 2015; Salewski et al., 2015b) . Characteristics of the included studies are presented in Table 1 .
Gathered data from 2537 animals (1204 in control group and 1333 in the treatment group) were pooled and analyzed together. Evaluation was conducted on 101 female and 24 male experimental animals. Contusion model was the most commonly used SCI induction model performed on 68 experiments, followed by 24 transection, 15 clip compression, 14 hemisection, and four balloon compression experiments. Experimentinduced injuries were severe in half and moderate in the other half. Mean time interval between injury and treatment was 9.3 ± 11.3 days (ranged from 1 to 56 days). In 40 experiments transplantation was performed right after injury induction (acute phase), in 74 procedures were 3-10 days apart (sub-acute phase), and in 11 this gap was equal to or more than two weeks (chronic phase). Intra-spinal transplantation was carried out in 114 experiments. Graft type was allogeneic in 77 experiments. The number of transplanted cells ranged from 1 Â 10 5 to 4 Â 10 7 cells per kilograms of the animals' body weight. Quality assessment of the included studies is presented in Table 2 .
Meta-analysis
Efficacy of neural stem cell transplantation on functional recovery. In literature review, 69 studies including Fig. 1 . Flowchart of including studies in the meta-analysis. 118 experiments had evaluated the efficacy of NSPC transplantation on functional recovery of subjects after SCI (Cummings et al., 2005; Iwanami et al., 2005; Okada et al., 2005; Pallini et al., 2005; Ziv et al., 2006; Guo et al., 2007 Guo et al., , 2012 Parr et al., 2007 Parr et al., , 2008a Tarasenko et al., 2007; Zhang et al., 2007; Bottai et al., 2008; Lowry et al., 2008; Pan et al., 2008; Hooshmand et al., 2009; Kumagai et al., 2009; Lee et al., 2009; Abematsu et al., 2010; Chen et al., 2010; Johnson et al., 2010; Tsuji et al., 2010; Yamane et al., 2010; Du et al., 2011; Kim et al., 2011 Kim et al., , 2012 Nori et al., 2011; Wang et al., 2011 Wang et al., , 2014 Xu et al., 2011; Yasuda et al., 2011; Cheng et al., 2012; Cusimano et al., 2012; Fujimoto et al., 2012; Gu et al., 2012; Kobayashi et al., 2012; Lu et al., 2012 Lu et al., , 2014 Amemori et al., 2013 Amemori et al., , 2015 He et al., 2013; Kumamaru et al., 2013; Nishimura et al., 2013; Nutt et al., 2013; Park et al., 2013; Xia et al., 2013; Yang et al., 2013; Hong et al., 2014; Hwang et al., 2014; Iwasaki et al., 2014; Nemati et al., 2014; Ormond et al., 2014; Sharp et al., 2014; Yuan et al., 2014; Iwai et al., 2015; Liu et al., 2015; Pomeshchik et al., 2015; Romanyuk et al., 2015; Yokota et al., 2015; Salewski et al., 2015a) . Findings of this section are presented in Fig. 2 . Transplantation of these cells significantly improved restoration of motor function in the subjects (Pooled SMD = 1.45; 95% CI: 1.23-1.67; p < 0.001; I 2 = 81.0%). Publication bias was not observed in this part of the study (Coefficient = 1.30; 95% CI: À0.49 to 3.09; p = 0.15). Due to a considerable heterogeneity (I 2 = 81.1%; p < 0.001), subgroup analysis was performed. According to the findings presented in Table 3 , injury model, intervention phase, transplanted cells numbers, and immunosuppressive administration were found to be the main sources of heterogeneity. Cell efficacy considerably dropped (SMD = 0.58; 95% CI: 0.16-0.99) when cells were used in clip compression induced SCIs model compared to transection (SMD = 2.18; 95% CI: 1.45-2.93) model. Moreover, this treatment improved motor function recovery to a greater extent when cells were transplanted in acute (SMD = 1.80; 95% CI: 1.36-2.24) or sub-acute (SMD = 1.38; 95% CI: 1.08-1.67) phases compared to the chronic phase (SMD = 1.04; 95% CI: 0.47-1.60) (p = 0.03). Findings also showed better functional recovery where more than 3 Â 10 6 cell dose/kg was transplanted (SMD = 1.74; 95% CI: 1.43-2.05) compared lower doses injection (SMD = 0.94; 95% CI: 0.67-1.22). Immunosuppressive administration provoked significantly lower efficacies (SMD = 0.87; 95% CI: 0.57-1.17).
In addition, co-treatment with growth factors (SMD = 0.93; 95% CI: À0.22 to 2.08) and Schwann cells or bone marrow-derived mesenchymal cells (SMD = 1.21; 95% CI: À0.24 to 2.65) hindered neural stem cells effects, while scaffold application (SMD = 2.19; 95% CI: 1.30-2.07) improved cells efficacy. Motor function recovery was also found to be lower when cells were transplanted in cervical injuries (SMD = 0.54; 95% CI: 0.05-1.03) compared to thoracic injuries (SMD = 1.52; 95% CI: 1.28-1.75). Finally, wildtype NSPC transplantation (SMD = 1.41; 95% CI: 1.18-1.64) and induced pluripotent stem cell-derived (iPScderived) NSPC (SMD = 1.64; 95% CI: 0.83-2.45) had similar effects on motor function recovery.
Efficacy of neural stem cell transplantation on sensory status.
Allodynia. Nine studies (Hofstetter et al., 2005; Macias et al., 2006; Hu et al., 2010; KarimiAbdolrezaee et al., 2010; Salazar et al., 2010; Piltti et al., 2013a,b; Sontag et al., 2013; Salewski et al., 2015b) including 11 experiments evaluated NSPCs efficacy on allodynia among the subjects (Fig. 3) . NSPC transplantation had no significant effect on allodynia (Pooled SMD = 0.08; 95% CI: À0.33 to 0.49; p = 0.69; I 2 = 58.4%). Study heterogeneity persuaded us to conduct subgroup analysis in this section as well. Since in all these surveys female mice were also included and intrathoracic spinal transplantation was performed, these factors were excluded from the subgroup analyses. As presented in Table 4 , none of the evaluated factors significantly influenced NSPCs efficacy on allodynia.
Hyperalgesia. Eleven surveys (Teng et al., 2002; Hofstetter et al., 2005; Macias et al., 2006; KarimiAbdolrezaee et al., 2010; Luo et al., 2013; Piltti et al., 2013a,b; van Gorp et al., 2013; Amemori et al., 2015; Salewski et al., 2015b; Yao et al., 2015) including 16 experiments examined NSPC efficacy of on hyperalgesia (Fig. 3) . Pooled analysis demonstrated that NSPC transplantation had no significant effect on hyperalgesia (Pooled SMD = 0.25; 95% CI: À0.10 to 0.60; p = 0.16; I 2 = 64.4%). However, subgroup analysis showed improved hyperalgesia to some extent when NSPCs were extracted from mice (SMD = 0.33; 95% CI: 0.02-0.67) rather than rats (SMD = À0.18; 95% CI: À0.56 to 0.21) or human (SMD = 0.37; 95% CI: À0.48 to 1.17). Transplantation of more than 3 Â 10 6 cell dose/kg (SMD = 0.37; 95% CI: À0.02 to 0.77) in the first day after injury induction (SMD = 0.33; 95% CI: À0.02 to 0.24) slightly improved hyperalgesia as well. Findings are presented in Table 5 .
DISCUSSION
The present study, for the first time, designed to review the data gathered from animal models evaluating of NSPC transplantation efficacy on functional recovery and neuropathic pain relief in SCI through a quantitative approach. Findings confirmed that NSPC transplantation could significantly improve motor function recovery in the studied animals. NSPC efficacy was affected by the injury model (compression, contusion, hemisection, and transection), intervention phase, transplanted cell number, and immunosuppressive administration. Scaffold use with transplanted NSPCs could also boost transplantation efficacy. In addition, mice-derived NSPCs were found to be considerably more effective for hyperalgesia alleviation than rat or human origin cells. Transplanted cell numbers and intervention phase were also reported to affect hyperalgesia improvement. Allodynia, on the other hand, was not affected by NSPC transplantation.
Reviews, on the other hand, have been reported improvement in NSPC implantation efficacy on motor 
function recovery too. For instance, Tetzlaff et al. also reported that most surveys have verified the positive effects of NSPC transplantation on motor function outcomes of the evaluated animals. However, they did not find the optimal source of NSPCs for this purpose (Tetzlaff et al., 2011) . In this regard, we performed subgroup analysis based on donor species and NSPC embryonic or adult source. No significant differences were observed between embryonic and adult NSPC effects on motor function recovery, or neuropathic pain relief. Mothe and Tator found relative improvements of motor function recovery in response to NSPC transplantation (Mothe and Tator, 2013) . Although, NSPCs are suitable sources for SCI alleviation, ethical issues on fetal human origin tissues and lack of autologous cell sources have limited their uses (Mothe and Tator, 2013) . Therefore, adult tissuederived NSPCs may be used for SCI treatment. In recent years, alternative sources were introduced for NSPC derivation. IPSC-derived NSPCs originated from reprogramed somatic cells provide an autologous source for NSPCs without ethical concerns. In spite of experimental studies with improved motor function recovery post iPSCderived NSPC transplantation in SCI cases, some studies depicted no significant effect. The present meta-analysis showed that both wild-type and iPSC-derived NSPCs could drastically improve motor function recovery. Previous studies demonstrated that iPSC-derived NSPCs provide therapeutic benefits via the same mechanisms as wild-type or embryonic stem cell-derived NPSCs . Transplantation of iPSC-derived NSPCs could improve myelin repair, axon regeneration, and neurotropic factors secretion while reduced secondary inflammatory responses, Fujimoto et al., 2012; Nutt et al., 2013; Romanyuk et al., 2015) . Therefore, similar efficacy of the two mentioned sources of stem cells in motor function recovery was not unexpected. Including seven studies in their systematic review, LeeKubli and Lu demonstrated promising survival, differentiation and therapeutic effect of iPSC-derived NSPC transplantation after SCI. However, they stated that ideal iPSC reprograming and differentiation remain unclear and need further investigation (Lee-Kubli and Lu, 2015) . Our results have reached to the conclusion as Lee-Kubli and Lu study.
We included 12 studies in which iPSC-derived NSPCs provoked a great efficacy differences in motor function recovery (Tsuji et al., 2010; Nori et al., 2011; Fujimoto et al., 2012; Nutt et al., 2013; Hong et al., 2014; Lu et al., 2014; Amemori et al., 2015; Liu et al., 2015; Pomeshchik et al., 2015; Romanyuk et al., 2015; Salewski et al., 2015b) . One plausible reason for such heterogeneity may be rooted in the age of somatic cell donor (embryonic or adult). Therefore, we performed more specific analyses, based on the iPSC embryonic or adult somatic source. In this context, results showed that efficacy of embryonic-derived iPSCs (SMD = 1.89; 95% CI: 0.93-2.84) was considerably higher than those with adult somatic source (SMD = 0.79; 95% CI: 0.32-1.25). The difference may be due to adult somatic tissue-derived iPSCs characteristics i.e., the cells displayed significant resistance to differentiation . Mothe and Tator, stated that adult human NSPCs were difficult to expand for sufficient cell transplantation. They also added that iPSCs could trigger Tcell induced immune response in syngeneic recipients (Mothe and Tator, 2013) . Moreover, adult tissue-derived iPSCs were not as safe as embryonic-derived clones which, could form teratoma in SCI implantation . However, our current knowledge regarding iPSC-derived NSPC tumorigenicity, safety, and alternative reprograming is still insufficient.
Motor function recovery post NSPC transplantation is generally affected by intervention phase. Findings revealed that a shorter time gap between injury induction and transplantation could improve the efficiency of the treatment. Accordingly, transplantation during acute and sub-acute phases is associated with better results compared to chronic phase. This might be due to the partial irreversible nature of the injuries in chronic phase (Oyinbo, 2011) . Similar efficacy of the acute and sub-acute phases has been the notable finding among the studies. This is incongruent with the current assumption, since acute phase inflammatory responses creates a cytotoxic environment, which is incompatible with the NSPC survival and differentiation and focuses on better results of the cell therapy in sub-acute phase than acute and chronic phases (Mothe and Tator, 2013) . The present study showed that treatment in the acute phase had even slightly higher efficacy than sub- acute phase. It seems that the early presence of neural stem cells at the lesion site post injury can slow down inflammatory processes and decrease neural deaths. Various studies have shown neural stem cell modulatory effects on inflammatory/immune responses (Lee et al., 2008a,b; Bacigaluppi et al., 2009; Ottoboni et al., 2015) . This is also rather compatible with our previous metaanalysis in which we showed higher efficiencies of bone marrow derived mesenchymal cell transplantation in neuropathic pain relief after SCI if the procedure carries out during the first 4 days of injury (Hosseini et al., 2015) . In the present meta-analysis, we found that the NSPC transplantation efficacy varied based on the injury induction model i.e. clip compression efficacy has found to be lower than the transection model. Different inflammatory processes seem to be the plausible explanation for this observation. In the transection model, the inflammatory processes are not activated in the first 12 h post injury and the nervous tissue is still viable at the edges of the cut point (Kao and chang, 1977) and NSPC transplantation can suspend inflammatory activation at the time. Yet, cell seeding has also been done using a scaffold in most of these surveys. In the compression model however, the inflammatory processes are activated from the first or second hour post-injury and the function and survival of the transplanted cells should be affected accordingly. Despite rare complete transection injuries in human, compression and contusion injuries are more prevalent (Bunge et al., 1993) . Therefore, caution should be taken if clinical trials with NSPCs are designed.
Due to major discrepancies, the optimum number of transplanted cells is still a matter of debate. Median number of the cells per kilograms of animal's body weight was 4.3 Â 10 6 (interquartile range = 1.1 Â 10 6 -2 Â 10 7 ). In the present study, the 3 Â 10 6 cell dose/kg cut-off point was chosen based on some clinical situations (Hosseini et al., 2015) . Higher doses have shown to provoke better functional recovery (Hosseini et al., 2015) . This could be due to NSPC survival chance at higher doses efficient connections in the injured tissue. Surprisingly, immunosuppressive administration has shown to decrease the efficacy in transplanted NSPC functional recovery after SCI (SMD = 0.79 vs. SMD = 1.91). This is extremely difficult to rationalize. Most in vivo and in vitro studies have shown inhibitory effects of immunosuppressive medications on transplantation rejection and its facilitative influence on cell survival. Moreover, these agents can decrease inflammatory responses activated by traumatic spinal injury and increases growth and axon branching speed at the lesion site (Madsen et al., 1998; Xu et al., 1998) . Immunosuppressive drug inhibitory effects on functional recovery might be due to their negative effects on wound and spinal cord healing (Park et al., 2013) . However, we did not observe significant association between immunosuppressive use and efficacy of bone marrow derived stem cell transplantation with neuropathic pain relief after SCI (Hosseini et al., 2015) . These findings are indicative of the need for further investigations on this matter.
The role of NSPC transplantation in neuropathic pain relief was another subject of this study. Analyses showed that NSPC transplantation could relieve hyperalgesia without any effect on allodynia. Eaton in his study showed that neural cell lines could alleviate neuropathic pains (Eaton, 2004) . He only included those surveys with genetically engineered cell lines capable of (Franchi et al., 2014) . In spite of our study that addresses central models, Franchi et al mainly focuses the chronic construction of the sciatic nerve model with a peripheral aspect suitable for neural injuries induction. Referring to the different mechanisms of peripheral and central pain models (Burnett and Zager, 2004; Scholz and Woolf, 2007; Oyinbo, 2011) , this controversy is predictable. According to Li and Lepski neural stem cell transplantation has no significant effect on sensory status after SCIs (Li and Lepski, 2013) . This might be due to the neural stem cell high tendency for glial cell differentiation. Some studies have a differentiation rate of 40% to glial cells post transplantation compared with much less rate for neuronal differentiation (Tarasenko , 2007) . These changes might exacerbate secondary injuries developed within the first hours post SCI and can persist through months or sometimes years after the insult (Rowland et al., 2008) . In our previous meta-analysis (Hosseini et al., 2015) , we showed that bone marrow-derived mesenchymal stem cell implantation could improve allodynia with no significant effects on hyperalgesia unless it was implanted during the acute phase of injury. Mesenchymal stem cells could attenuate most unfavorable acute and chronic damages in the injured spinal cord (Wright et al., 2007; Teixeira et al., 2013) . Implanted cells have a neuroprotective role (Uccelli et al., 2008) and can reduce proinflammatory cytokines, reactive oxygen species, and asteriogliosis (Abrams et al., 2009 ). These cells can also enhance host neural stem cell to oligodendrocytes differentiation and stimulate re-myelination (Rivera et al., 2006) . However, NSPCs have less immunomodulatory properties and are apt to differentiate into astrocytes. Since NSPCs can develop some degree of allodynia and hyperalgesia in SCI animals (Hofstetter et al., 2005; Macias et al., 2006) , their transplantation cannot significantly improve allodynia and hyperalgesia in the SCI animal models. According to Mothe and Tator, only predifferentiated NSPCs grafts in astrocytes can improve allodynia (Mothe and Tator, 2013) .
Finally, subgroup analysis showed more improvements in hyperalgesia when NSPCs were extracted from mice rather than rats or human. Several reasons are required to explain this phenomenon. According to Mothe and Tator human derived NSPCs were either unavailable or difficult to grow (Mothe and Tator, 2013) . In addition, Drukker and Benvenisty showed that human-derived NSPCs rejection imposed a great threat to their clinical use in regenerative medicine (Drukker and Benvenisty, 2004) . In contrast, mouse NSPCs are a non-immunogenic immune-privileged tissue, and can be transplanted into allogeneic recipients without immunosuppressive regimens side effects (Hori et al., 2003) .
STRENGTHS AND LIMITATIONS
In the present study, extended electronic search, authors contact, and manual webpage search were used to include maximum number of articles and gray literature. This method provided us with 74 studies and 125 experiments in the meta-analysis. Accordingly, data from 2382 animal subjects were pooled together and then analyzed. Absence of publication bias was one of the strengths of this survey. Heterogeneity in analyses was one of the study limitations, which was overcome through subgroup analysis. Lack of observers blinded to some included studies was another limitation. However, since in subgroup analysis neutrality is irrelevant to NSPCs transplantation efficacy on functional recovery and sensory condition, bias would accordingly be at its minimum levels.
CONCLUSION
Findings of the present meta-analysis showed that the efficacy of NSPC transplantation depends on the injury model, intervention phase, number of transplanted cells, immunosuppressive medications, and probably the cell source. The efficacy of this treatment method is higher in transection and contusion injury models than compression one. The shorter the interval between injury and treatment, led to the better the functional recovery and sensory condition. The best treatment dose was also found to be higher than 3 Â 10 6 cell dose/kg. Immunosuppressive drug administration was found to negatively affect motor function recovery. Scaffold use could also boost NSPC efficacy on motor function recovery.
